Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 528 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetic Study in Healthy Volunteers Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects

NCT06036784
View directory record Official record
Conditions
Postbariatric Hypoglycemia
Interventions
MBX 1416 (Part A), MBX 1416 (Part B), Placebo, MBX 1416 (Part C)
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TMC207 +/- Rifabutin/Rifampin

NCT01341184
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifabutin, Rifampin, TMC207
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days

NCT01786915
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bendavia 10mg, Bendavia 50mg, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers

NCT01375946
View directory record Official record
Conditions
Healthy
Interventions
AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Multiple Doses of Lasmiditan in Healthy Participants

NCT03252015
View directory record Official record
Conditions
Healthy
Interventions
Probe Drug Cocktail, Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

NCT01339897
View directory record Official record
Conditions
Healthy
Interventions
5 mg/N6022, Placebo, 10mg/N6022, 20mg/N6022
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study

NCT01105780
View directory record Official record
Conditions
Healthy
Interventions
Placebo, JNJ-41443532
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers

NCT00647868
View directory record Official record
Conditions
Hypogonadism
Interventions
testosterone
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
20 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2018 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

NCT01188668
View directory record Official record
Conditions
Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human
Interventions
Aripiprazole, Aripiprazole + desvenlafaxine succinate sustained release
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Pharmacokinetic Study of Diazoxide Choline Coated vs. Uncoated Formulations

NCT00688857
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Diazoxide choline
Drug
Lead sponsor
Essentialis, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Nov 8, 2010 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers

NCT04570644
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease
Interventions
ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)
Drug
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
55 Years to 79 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations

NCT01979484
View directory record Official record
Conditions
Pharmacokinetic Assessments in Healthy Volunteers
Interventions
PPI-668 capsule, PPI-668 tablet
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935

NCT02201056
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

NCT03733561
View directory record Official record
Conditions
Parkinson Disease
Interventions
LY03003, Neupro 4Mg/24Hr Transdermal Patch
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Examine the Absorption of GSK561679 in Healthy Male Volunteers

NCT00539136
View directory record Official record
Conditions
Healthy Subjects
Interventions
GSK561679 tablet or solution
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial Investigating Lu AF28996 in Healthy Adult Participants

NCT06277609
View directory record Official record
Conditions
Healthy Participants
Interventions
Lu AF28996, Acetylsalicylic Acid, Mefenamic Acid, Amoxicillin/clavulanic acid
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers

NCT01136928
View directory record Official record
Conditions
Healthy Volunteers
Interventions
American ginseng
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-881 and HyQvia in Healthy Adults

NCT06895967
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-881, HyQvia, SC Investigational Needle Sets
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TA-65 Pharmacokinetic Study

NCT02731807
View directory record Official record
Conditions
Healthy
Interventions
Dose A: TA-65 24mg, powder, Dose B: TA-65, 8mg, powder, Dose C: TA-65 3.2mg, capsule, Dose D: TA-65 8mg, capsule, Dose E: TA-65 32mg, capsule
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
22 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

NCT01916850
View directory record Official record
Conditions
Healthy
Interventions
LX4211 400 mg, LX4211 800 mg, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers

NCT04527718
View directory record Official record
Conditions
Healthy
Interventions
Placebo, 611
Drug
Lead sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers

NCT02039817
View directory record Official record
Conditions
Renal Impairment, Renal Insufficiency, Kidney Disease, Kidney Diseases
Interventions
IDN-6556
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
DeLand, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 10, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers

NCT02750748
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone, Intravail
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 10, 2026, 5:21 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

NCT02769065
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 10, 2026, 5:21 PM EDT